Scholarlink

Background <p>Multiple myeloma (MM) is a heterogeneous malignancy with prognosis significantly affected by high-risk cytogenetic abnormalities (HRCAs). Traditional detection using fluorescence in situ hybridisation is invasive and limited in capturing disease heterogeneity. We aimed to develop and validate radiomics model based on pretreatment [18F] fluoro-deoxyglucose (FDG) positron emission tomography/computed tomographic (18F-FDG PET/CT) imaging to non-invasively predict HRCAs in newly diagnosed MM patients.</p> Results <p>Among the 42 candidate models, the Decision Tree classifier utilizing PET active lesions features demonstrated optimal performance in the validation cohort, exhibiting excellent predictive ability (Area Under the Curve (AUC) = 0.89), significantly outperforming the PET metrics model (AUC = 0.84) and clinical model (AUC = 0.74). SHapley Additive exPlanations analysis identified the PET-derived feature as the most important contributor to the model’s predictive capacity. The model stratified patients into high-risk and low-risk groups, with the high-risk group exhibiting significantly worse PFS and OS (median PFS: high-risk 24.5 months vs. low-risk 29 months; <i>p</i> = 0.0360; median OS: high-risk 33.5 months vs. low-risk 50 months; <i>p</i> = 0.0023).</p> Conclusion <p>As a non-invasive imaging biomarker, PET/CT radiomics holds potential for predicting high-risk cytogenetic status and facilitating patient prognosis stratification Further large-scale, multi-center prospective validations are essential to confirm its utility for personalized therapeutic decision-making in MM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A feasibility study of [18F] FDG PET/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月15日

查看全文
  • Hong Chen,
  • Jingxin Han,
  • Haozhe Huang,
  • Qi He,
  • Xinqi Ren,
  • Fan Yu,
  • Chunkang Chang,
  • Xuehai Ding,
  • Quanyong Luo

摘要

Background

Multiple myeloma (MM) is a heterogeneous malignancy with prognosis significantly affected by high-risk cytogenetic abnormalities (HRCAs). Traditional detection using fluorescence in situ hybridisation is invasive and limited in capturing disease heterogeneity. We aimed to develop and validate radiomics model based on pretreatment [18F] fluoro-deoxyglucose (FDG) positron emission tomography/computed tomographic (18F-FDG PET/CT) imaging to non-invasively predict HRCAs in newly diagnosed MM patients.

Results

Among the 42 candidate models, the Decision Tree classifier utilizing PET active lesions features demonstrated optimal performance in the validation cohort, exhibiting excellent predictive ability (Area Under the Curve (AUC) = 0.89), significantly outperforming the PET metrics model (AUC = 0.84) and clinical model (AUC = 0.74). SHapley Additive exPlanations analysis identified the PET-derived feature as the most important contributor to the model’s predictive capacity. The model stratified patients into high-risk and low-risk groups, with the high-risk group exhibiting significantly worse PFS and OS (median PFS: high-risk 24.5 months vs. low-risk 29 months; p = 0.0360; median OS: high-risk 33.5 months vs. low-risk 50 months; p = 0.0023).

Conclusion

As a non-invasive imaging biomarker, PET/CT radiomics holds potential for predicting high-risk cytogenetic status and facilitating patient prognosis stratification Further large-scale, multi-center prospective validations are essential to confirm its utility for personalized therapeutic decision-making in MM.